Hims & Hers Health reported a 38% revenue increase in Q2 to $753.2 million and raised its full-year revenue forecast to $3.1–$3.3 billion. Despite a six-point drop in gross margin to 64%, the company is evolving into a distribution platform for branded weight-loss drugs, which boosts revenue but compresses margins. The company is also focusing on manufacturing peptides, a weight-adjacent product, to reduce reliance on partnerships. The positive outlook and strategic shifts suggest potential upside following a recent post-earnings stock decline.
Berger Montague PC is investigating Hims & Hers Health, Inc. for possible breaches of fiduciary duties including improper sharing of private health data with advertisers, deceptive billing practices, and making subscription cancellations difficult. T...
Hims & Hers Health reported Q2 revenue of $753.21 million, up 38% year-over-year, beating estimates. However, the company posted a wider-than-expected GAAP loss of $0.37 per share due to declining gross margins and rising operating expenses. Legal tr...
Anthropic will embed persistent watermarks and provenance metadata in all AI-generated content from its Claude models in the EU starting August 2, complying with the EU AI Act for transparency. Sea Limited's stock rallied after beating Q2 revenue exp...
Hims & Hers Health reported a 38% year-over-year revenue increase to $753.2 million in Q2 2026, surpassing analyst expectations of $699 million. However, the company posted a larger-than-expected loss of $0.37 per share, driven by restructuring costs...
Hims & Hers Health, Inc. reported a second-quarter 2026 earnings per share (EPS) loss of $0.10, missing the expected loss of $0.05. However, the company exceeded revenue expectations with $753.21 million, above the $698.89 million estimate, driven by...
